UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME
UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME
LaxativesLaxatives• Improve constipation, no global improvement• Lack of good evidence• Aggravate abdominal pain / bloating• GOR : 2C• NNT :2‐4
Tegaserod• Only 5HT4 Receptor agonists approved• Stimulates release of neurotransmitter and increasecolonic motility• GOR : 1A• Cardiovascular side effects : angina ,AMI ,CVA• Remove from market since Mar 2007• More selective 5HT4 agonists under investigation
- Page 13 and 14: DIAGNOSIS
- Page 15 and 16: Manning criteria• > 3 of the foll
- Page 17 and 18: Symptom‐based diagnosticcriteriaL
- Page 19 and 20: How alarming ?SensitivitySpecificit
- Page 21 and 22: Diagnosis• Consensus statement is
- Page 23 and 24: Emerging specific Investigations•
- Page 25 and 26: PATHOPHYSIOLOGY
- Page 27 and 28: Genetic predisposition• Similar s
- Page 29 and 30: Visceral Hypersensitivity andBrain
- Page 31 and 32: Small Intestine BacterialOvergrowth
- Page 33 and 34: Psychological Dysfunction• Not et
- Page 35 and 36: General PrincipleNon pharmacologica
- Page 37: Compare components of placebo effec
- Page 40 and 41: Outcomes at six week follow-upKaptc
- Page 42 and 43: Patient Education• Explain about
- Page 44: Psychosocial Therapies• Interpers
- Page 48 and 49: Pharmacological treatment• IBS wi
- Page 51 and 52: NNT=5(95% CI 4‐9 )
- Page 53 and 54: Anti‐depressantsSSRI• Less publ
- Page 55 and 56: Psychosocial TherapiesCBT• Cognit
- Page 57 and 58: IBS WITH DIARRHEA
- Page 59 and 60: Alosetron• 1 st IBS specific medi
- Page 61 and 62: Summary of Treatment forIBS‐assoc
- Page 63: FiberNNT: 11(95%CI ,5‐100)
- Page 69 and 70: Lubiprostone• Selective C‐2 chl
- Page 71 and 72: Summary of Treatment forIBS‐assoc
- Page 73 and 74: Alternative Therapies• Peppermint
- Page 77 and 78: CASE SCENARIOIS IT REALLY IBS?
- Page 79 and 80: Ms.Cheung• Is it IBS?• Given ch
- Page 81 and 82: Mr.Leung• Is it IBS?• CT abdome
- Page 83 and 84: Points to note• Red flags for a c
Tegaserod• Only 5HT4 Receptor agonists approved• Stimulates release of neurotransmitter and increasecolonic motility• GOR : 1A• Cardiovascular side effects : angina ,AMI ,CVA• Remove from market since Mar 2007• More selective 5HT4 agonists under investigation
Change language